Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Vaginal metabolome: towards a minimally invasive diagnosis of microbial invasion of the amniotic cavity in women with preterm labor.

Vicente-Muñoz S, Cobo T, Puchades-Carrasco L, Sánchez-García AB, Agustí N, Palacio M, Pineda-Lucena A, Gratacós E.

Sci Rep. 2020 Mar 25;10(1):5465. doi: 10.1038/s41598-020-62542-6.

2.

Glutamine/glutamate metabolism rewiring in reprogrammed human hepatocyte-like cells.

Ballester M, Sentandreu E, Luongo G, Santamaria R, Bolonio M, Alcoriza-Balaguer MI, Palomino-Schätzlein M, Pineda-Lucena A, Castell J, Lahoz A, Bort R.

Sci Rep. 2019 Nov 29;9(1):17978. doi: 10.1038/s41598-019-54357-x.

3.

Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.

Rabal O, Sánchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, García-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Tan H, Wu W, Xu M, Pineda-Lucena A, Garcia-Osta A, Oyarzabal J.

ACS Chem Neurosci. 2019 Sep 18;10(9):4076-4101. doi: 10.1021/acschemneuro.9b00303. Epub 2019 Sep 4.

PMID:
31441641
4.

Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression.

Arroyo-Crespo JJ, Armiñán A, Charbonnier D, Deladriere C, Palomino-Schätzlein M, Lamas-Domingo R, Forteza J, Pineda-Lucena A, Vicent MJ.

Int J Cancer. 2019 Oct 15;145(8):2267-2281. doi: 10.1002/ijc.32270. Epub 2019 Apr 2.

5.

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.

Gómez-Cebrián N, Rojas-Benedicto A, Albors-Vaquer A, López-Guerrero JA, Pineda-Lucena A, Puchades-Carrasco L.

Metabolites. 2019 Mar 8;9(3). pii: E48. doi: 10.3390/metabo9030048. Review.

6.

EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology.

Brennecke P, Rasina D, Aubi O, Herzog K, Landskron J, Cautain B, Vicente F, Quintana J, Mestres J, Stechmann B, Ellinger B, Brea J, Kolanowski JL, Pilarski R, Orzaez M, Pineda-Lucena A, Laraia L, Nami F, Zielenkiewicz P, Paruch K, Hansen E, von Kries JP, Neuenschwander M, Specker E, Bartunek P, Simova S, Leśnikowski Z, Krauss S, Lehtiö L, Bilitewski U, Brönstrup M, Taskén K, Jirgensons A, Lickert H, Clausen MH, Andersen JH, Vicent MJ, Genilloud O, Martinez A, Nazaré M, Fecke W, Gribbon P.

SLAS Discov. 2019 Mar;24(3):398-413. doi: 10.1177/2472555218816276. Epub 2019 Jan 7.

7.

A translational approach to assess the metabolomic impact of stabilized gold nanoparticles by NMR spectroscopy.

Herance JR, García H, Gutiérrez-Carcedo P, Navalón S, Pineda-Lucena A, Palomino-Schätzlein M.

Analyst. 2019 Feb 11;144(4):1265-1274. doi: 10.1039/c8an01827h.

PMID:
30547176
8.

MYC Induces a Hybrid Energetics Program Early in Cell Reprogramming.

Prieto J, Seo AY, León M, Santacatterina F, Torresano L, Palomino-Schätzlein M, Giménez K, Vallet-Sánchez A, Ponsoda X, Pineda-Lucena A, Cuezva JM, Lippincott-Schwartz J, Torres J.

Stem Cell Reports. 2018 Dec 11;11(6):1479-1492. doi: 10.1016/j.stemcr.2018.10.018. Epub 2018 Nov 21.

9.

Mobilisation Mechanism of Pathogenicity Islands by Endogenous Phages in Staphylococcus aureus clinical strains.

Cervera-Alamar M, Guzmán-Markevitch K, Žiemytė M, Ortí L, Bernabé-Quispe P, Pineda-Lucena A, Pemán J, Tormo-Mas MÁ.

Sci Rep. 2018 Nov 13;8(1):16742. doi: 10.1038/s41598-018-34918-2.

10.

Corrigendum to "A Drosophila model of GDAP1 function reveals the involvement of insulin signalling in the mitochondria-dependent neuromuscular degeneration" [Biochim. Biophys. Acta 1863 (2017) 801-809].

López Del Amo V, Palomino-Schätzlein M, Seco-Cervera M, García-Giménez JL, Pallardó FV, Pineda-Lucena A, Galindo MI.

Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):261. doi: 10.1016/j.bbadis.2018.11.001. Epub 2018 Nov 10. No abstract available.

11.

Metabolic fingerprint of insulin resistance in human polymorphonuclear leucocytes.

Palomino-Schätzlein M, Simó R, Hernández C, Ciudin A, Mateos-Gregorio P, Hernández-Mijares A, Pineda-Lucena A, Herance JR.

PLoS One. 2018 Jul 13;13(7):e0199351. doi: 10.1371/journal.pone.0199351. eCollection 2018.

12.

Rapid two-dimensional ALSOFAST-HSQC experiment for metabolomics and fluxomics studies: application to a 13C-enriched cancer cell model treated with gold nanoparticles.

Schätzlein MP, Becker J, Schulze-Sünninghausen D, Pineda-Lucena A, Herance JR, Luy B.

Anal Bioanal Chem. 2018 Apr;410(11):2793-2804. doi: 10.1007/s00216-018-0961-6. Epub 2018 Feb 26.

PMID:
29480388
13.

Metabolomics facilitates the discrimination of the specific anti-cancer effects of free- and polymer-conjugated doxorubicin in breast cancer models.

Armiñán A, Palomino-Schätzlein M, Deladriere C, Arroyo-Crespo JJ, Vicente-Ruiz S, Vicent MJ, Pineda-Lucena A.

Biomaterials. 2018 Apr;162:144-153. doi: 10.1016/j.biomaterials.2018.02.015. Epub 2018 Feb 8.

14.

Development of inhibitors of receptor protein tyrosine phosphatase β/ζ (PTPRZ1) as candidates for CNS disorders.

Pastor M, Fernández-Calle R, Di Geronimo B, Vicente-Rodríguez M, Zapico JM, Gramage E, Coderch C, Pérez-García C, Lasek AW, Puchades-Carrasco L, Pineda-Lucena A, de Pascual-Teresa B, Herradón G, Ramos A.

Eur J Med Chem. 2018 Jan 20;144:318-329. doi: 10.1016/j.ejmech.2017.11.080. Epub 2017 Nov 28.

15.

Correction: Assessment of gold nanoparticles on human peripheral blood cells by metabolic profiling with 1H-NMR spectroscopy, a novel translational approach on a patient-specific basis.

Palomino-Schätzlein M, García H, Gutiérrez-Carcedo P, Pineda-Lucena A, Herance JR.

PLoS One. 2017 Dec 11;12(12):e0189748. doi: 10.1371/journal.pone.0189748. eCollection 2017.

16.

Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.

Pérez-Rambla C, Puchades-Carrasco L, García-Flores M, Rubio-Briones J, López-Guerrero JA, Pineda-Lucena A.

Metabolomics. 2017;13(5):52. doi: 10.1007/s11306-017-1194-y. Epub 2017 Mar 9.

17.

Assessment of gold nanoparticles on human peripheral blood cells by metabolic profiling with 1H-NMR spectroscopy, a novel translational approach on a patient-specific basis.

Palomino-Schätzlein M, García H, Gutiérrez-Carcedo P, Pineda-Lucena A, Herance JR.

PLoS One. 2017 Aug 9;12(8):e0182985. doi: 10.1371/journal.pone.0182985. eCollection 2017. Erratum in: PLoS One. 2017 Dec 11;12 (12 ):e0189748.

18.

Metabolomics Applications in Precision Medicine: An Oncological Perspective.

Puchades-Carrasco L, Pineda-Lucena A.

Curr Top Med Chem. 2017;17(24):2740-2751. doi: 10.2174/1568026617666170707120034. Review.

19.

Fragment Binding to β-Secretase 1 without Catalytic Aspartate Interactions Identified via Orthogonal Screening Approaches.

Rombouts FJR, Alexander R, Cleiren E, De Groot A, Carpentier M, Dijkmans J, Fierens K, Masure S, Moechars D, Palomino-Schätzlein M, Pineda-Lucena A, Trabanco AA, Van Glabbeek D, Vos A, Tresadern G.

ACS Omega. 2017 Feb 28;2(2):685-697. doi: 10.1021/acsomega.6b00482. Epub 2017 Feb 24.

20.

The PipX Protein, When Not Bound to Its Targets, Has Its Signaling C-Terminal Helix in a Flexed Conformation.

Forcada-Nadal A, Palomino-Schätzlein M, Neira JL, Pineda-Lucena A, Rubio V.

Biochemistry. 2017 Jun 27;56(25):3211-3224. doi: 10.1021/acs.biochem.7b00230. Epub 2017 Jun 14.

PMID:
28581722
21.

A Drosophila model of GDAP1 function reveals the involvement of insulin signalling in the mitochondria-dependent neuromuscular degeneration.

López Del Amo V, Palomino-Schätzlein M, Seco-Cervera M, García-Giménez JL, Pallardó FV, Pineda-Lucena A, Galindo MI.

Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):801-809. doi: 10.1016/j.bbadis.2017.01.003. Epub 2017 Jan 6. Erratum in: Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):261.

22.

Pathophysiologic processes have an impact on the plasma metabolomic signature of endometriosis patients.

Vicente-Muñoz S, Morcillo I, Puchades-Carrasco L, Payá V, Pellicer A, Pineda-Lucena A.

Fertil Steril. 2016 Dec;106(7):1733-1741.e1. doi: 10.1016/j.fertnstert.2016.09.014. Epub 2016 Oct 25.

PMID:
27793377
23.

Multibody cofactor and substrate molecular recognition in the myo-inositol monophosphatase enzyme.

Ferruz N, Tresadern G, Pineda-Lucena A, De Fabritiis G.

Sci Rep. 2016 Jul 21;6:30275. doi: 10.1038/srep30275.

24.

Profiling human blood serum metabolites by nuclear magnetic resonance spectroscopy: a comprehensive tool for the evaluation of hemodialysis efficiency.

Kromke M, Palomino-Schätzlein M, Mayer H, Pfeffer S, Pineda-Lucena A, Luy B, Hausberg M, Muhle-Goll C.

Transl Res. 2016 May;171:71-82.e1-9. doi: 10.1016/j.trsl.2016.02.003. Epub 2016 Feb 10.

PMID:
26924041
25.

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.

Puchades-Carrasco L, Jantus-Lewintre E, Pérez-Rambla C, García-García F, Lucas R, Calabuig S, Blasco A, Dopazo J, Camps C, Pineda-Lucena A.

Oncotarget. 2016 Mar 15;7(11):12904-16. doi: 10.18632/oncotarget.7354.

26.

Bioinformatics tools for the analysis of NMR metabolomics studies focused on the identification of clinically relevant biomarkers.

Puchades-Carrasco L, Palomino-Schätzlein M, Pérez-Rambla C, Pineda-Lucena A.

Brief Bioinform. 2016 May;17(3):541-52. doi: 10.1093/bib/bbv077. Epub 2015 Sep 4. Review.

PMID:
26342127
27.

Nuclear magnetic resonance metabolomic profiling of urine provides a noninvasive alternative to the identification of biomarkers associated with endometriosis.

Vicente-Muñoz S, Morcillo I, Puchades-Carrasco L, Payá V, Pellicer A, Pineda-Lucena A.

Fertil Steril. 2015 Nov;104(5):1202-9. doi: 10.1016/j.fertnstert.2015.07.1149. Epub 2015 Aug 18.

PMID:
26297644
28.

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P.

Cancer Cell. 2015 Aug 10;28(2):170-82. doi: 10.1016/j.ccell.2015.07.001.

29.

Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.

Palomino-Schätzlein M, Pineda-Lucena A.

Methods Mol Biol. 2016;1336:211-23. doi: 10.1007/978-1-4939-2926-9_16.

PMID:
26231718
30.

In Vivo Detection of Perinatal Brain Metabolite Changes in a Rabbit Model of Intrauterine Growth Restriction (IUGR).

Simões RV, Muñoz-Moreno E, Carbajo RJ, González-Tendero A, Illa M, Sanz-Cortés M, Pineda-Lucena A, Gratacós E.

PLoS One. 2015 Jul 24;10(7):e0131310. doi: 10.1371/journal.pone.0131310. eCollection 2015.

31.

Metabolomics in pharmaceutical research and development.

Puchades-Carrasco L, Pineda-Lucena A.

Curr Opin Biotechnol. 2015 Dec;35:73-7. doi: 10.1016/j.copbio.2015.04.004. Epub 2015 Apr 17. Review.

PMID:
25900094
32.

Apaf-1 inhibitors protect from unwanted cell death in in vivo models of kidney ischemia and chemotherapy induced ototoxicity.

Orzáez M, Sancho M, Marchán S, Mondragón L, Montava R, Valero JG, Landeta O, Basañez G, Carbajo RJ, Pineda-Lucena A, Bujons J, Moure A, Messeguer A, Lagunas C, Herrero C, Pérez-Payá E.

PLoS One. 2014 Oct 20;9(10):e110979. doi: 10.1371/journal.pone.0110979. eCollection 2014.

33.

Dietary gallic acid and anthocyanin cytotoxicity on human fibrosarcoma HT1080 cells. A study on the mode of action.

Filipiak K, Hidalgo M, Silvan JM, Fabre B, Carbajo RJ, Pineda-Lucena A, Ramos A, de Pascual-Teresa B, de Pascual-Teresa S.

Food Funct. 2014 Feb;5(2):381-9. doi: 10.1039/c3fo60465a.

PMID:
24413695
34.

Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase.

Mosulén S, Pineda-Lucena A, Carbajo RJ.

Biomol NMR Assign. 2015 Apr;9(1):15-9. doi: 10.1007/s12104-013-9536-9. Epub 2014 Jan 7.

PMID:
24395156
35.

Metabolomic profile of umbilical cord blood plasma from early and late intrauterine growth restricted (IUGR) neonates with and without signs of brain vasodilation.

Sanz-Cortés M, Carbajo RJ, Crispi F, Figueras F, Pineda-Lucena A, Gratacós E.

PLoS One. 2013 Dec 2;8(12):e80121. doi: 10.1371/journal.pone.0080121. eCollection 2013.

36.

Progress towards water-soluble triazole-based selective MMP-2 inhibitors.

Fabre B, Filipiak K, Zapico JM, Díaz N, Carbajo RJ, Schott AK, Martínez-Alcázar MP, Suárez D, Pineda-Lucena A, Ramos A, de Pascual-Teresa B.

Org Biomol Chem. 2013 Oct 14;11(38):6623-41. doi: 10.1039/c3ob41046c. Epub 2013 Aug 30.

PMID:
23989288
37.

Optimised protocols for the metabolic profiling of S. cerevisiae by 1H-NMR and HRMAS spectroscopy.

Palomino-Schätzlein M, Molina-Navarro MM, Tormos-Pérez M, Rodríguez-Navarro S, Pineda-Lucena A.

Anal Bioanal Chem. 2013 Oct;405(26):8431-41. doi: 10.1007/s00216-013-7271-9. Epub 2013 Aug 14.

PMID:
23942588
38.

Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission.

Puchades-Carrasco L, Lecumberri R, Martínez-López J, Lahuerta JJ, Mateos MV, Prósper F, San-Miguel JF, Pineda-Lucena A.

Clin Cancer Res. 2013 Sep 1;19(17):4770-9. doi: 10.1158/1078-0432.CCR-12-2917. Epub 2013 Jul 19.

39.

Synthesis of fucosyl-N-acetylglucosamine disaccharides by transfucosylation using α-L-fucosidases from Lactobacillus casei.

Rodríguez-Díaz J, Carbajo RJ, Pineda-Lucena A, Monedero V, Yebra MJ.

Appl Environ Microbiol. 2013 Jun;79(12):3847-50. doi: 10.1128/AEM.00229-13. Epub 2013 Mar 29.

40.

Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.

Gozalbes R, Mosulén S, Ortí L, Rodríguez-Díaz J, Carbajo RJ, Melnyk P, Pineda-Lucena A.

Bioorg Med Chem. 2013 Apr 1;21(7):1944-51. doi: 10.1016/j.bmc.2013.01.033. Epub 2013 Jan 31.

PMID:
23415087
41.

Differential metabolic profiling of non-pure trisomy 21 human preimplantation embryos.

Sánchez-Ribas I, Riqueros M, Vime P, Puchades-Carrasco L, Jönsson T, Pineda-Lucena A, Ballesteros A, Domínguez F, Simón C.

Fertil Steril. 2012 Nov;98(5):1157-64.e1-2. doi: 10.1016/j.fertnstert.2012.07.1145. Epub 2012 Sep 6.

PMID:
22959456
42.

Identification of first proadrenomedullin N-terminal 20 peptide (PAMP) modulator by means of virtual screening and NMR interaction experiments.

Roldós V, Carbajo RJ, Schott AK, Pineda-Lucena A, Ochoa-Callejero L, Martínez A, Ramos A, de Pascual-Teresa B.

Eur J Med Chem. 2012 Sep;55:262-72. doi: 10.1016/j.ejmech.2012.07.031. Epub 2012 Jul 27.

PMID:
22884224
43.

GSK3-SCF(FBXW7) targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase.

Pérez-Benavente B, García JL, Rodríguez MS, Pineda-Lucena A, Piechaczyk M, Font de Mora J, Farràs R.

Oncogene. 2013 Apr 25;32(17):2189-99. doi: 10.1038/onc.2012.235. Epub 2012 Jun 18.

PMID:
22710716
44.

Novel compounds produced by Streptomyces lydicus NRRL 2433 engineered mutants altered in the biosynthesis of streptolydigin.

Gómez C, Olano C, Palomino-Schätzlein M, Pineda-Lucena A, Carbajo RJ, Braña AF, Méndez C, Salas JA.

J Antibiot (Tokyo). 2012 Jul;65(7):341-8. doi: 10.1038/ja.2012.37. Epub 2012 May 9.

PMID:
22569159
45.

Structure of minimal tetratricopeptide repeat domain protein Tah1 reveals mechanism of its interaction with Pih1 and Hsp90.

Jiménez B, Ugwu F, Zhao R, Ortí L, Makhnevych T, Pineda-Lucena A, Houry WA.

J Biol Chem. 2012 Feb 17;287(8):5698-709. doi: 10.1074/jbc.M111.287458. Epub 2011 Dec 16.

46.

Evaluation of nonpolar metabolites in plant extracts by 13C NMR spectroscopy.

Palomino-Schätzlein M, Escrig PV, Boira H, Primo J, Pineda-Lucena A, Cabedo N.

J Agric Food Chem. 2011 Nov 9;59(21):11407-16. doi: 10.1021/jf2030902. Epub 2011 Oct 7.

PMID:
21955286
47.

Amino acid precursor supply in the biosynthesis of the RNA polymerase inhibitor streptolydigin by Streptomyces lydicus.

Gómez C, Horna DH, Olano C, Palomino-Schätzlein M, Pineda-Lucena A, Carbajo RJ, Braña AF, Méndez C, Salas JA.

J Bacteriol. 2011 Aug;193(16):4214-23. doi: 10.1128/JB.05062-11. Epub 2011 Jun 10.

48.

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.

Sancho M, Herrera AE, Gortat A, Carbajo RJ, Pineda-Lucena A, Orzáez M, Pérez-Payá E.

Hum Mol Genet. 2011 Sep 15;20(18):3545-53. doi: 10.1093/hmg/ddr271. Epub 2011 Jun 9.

PMID:
21659333
49.

NMR structure and dynamics of recombinant wild type and mutated jerdostatin, a selective inhibitor of integrin α1β1.

Carbajo RJ, Sanz L, Mosulén S, Pérez A, Marcinkiewicz C, Pineda-Lucena A, Calvete JJ.

Proteins. 2011 Aug;79(8):2530-42. doi: 10.1002/prot.23076. Epub 2011 Jun 7.

PMID:
21656569
50.

Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.

Zapico JM, Serra P, García-Sanmartín J, Filipiak K, Carbajo RJ, Schott AK, Pineda-Lucena A, Martínez A, Martín-Santamaría S, de Pascual-Teresa B, Ramos A.

Org Biomol Chem. 2011 Jun 21;9(12):4587-99. doi: 10.1039/c0ob00852d. Epub 2011 May 6.

PMID:
21552627

Supplemental Content

Loading ...
Support Center